Business Focus - The company is hosting a 2025 Investor Event focused on changing clinical practice[22] - The company's long-term growth aspirations extend to a total addressable market of ~150+ million hospital patients and ~100+ million homecare patients[35] - The company provides physicians with speaking fees or charitable donations for their time, and reimburses expenses related to events[10] Clinical Practice and Evidence - Nasal high flow clinical papers are published annually, supporting global practice change[25] - There are 193 ongoing clinical trials across 25+ countries for Anaesthesia Optiflow[100] - Clinical evidence is driving practice change, particularly in Anaesthesia Optiflow, with numerous publications including systematic reviews, randomized controlled trials, and non-comparative studies[97, 98] - Nasal high flow is recommended or acknowledged alongside other oxygenation techniques in various guidelines across multiple countries[105] Product Application - Optiflow is used in various settings including neonatal care, anaesthesia, the ED, and the ward[9, 87, 108] - The company's therapies cover a range of applications including invasive and noninvasive ventilation, hospital respiratory support, anesthesia support, home respiratory care, and obstructive sleep apnea[35]